Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,189
  • Shares Outstanding, K 69,307
  • Annual Sales, $ 35,280 K
  • Annual Income, $ -169,030 K
  • EBIT $ -290 M
  • EBITDA $ -283 M
  • 60-Month Beta 1.48
  • Price/Sales 12.12
  • Price/Cash Flow N/A
  • Price/Book 0.69

Options Overview Details

View History
  • Implied Volatility 393.78% ( -19.04%)
  • Historical Volatility 78.04%
  • IV Percentile 97%
  • IV Rank 69.48%
  • IV High 546.07% on 11/04/25
  • IV Low 47.10% on 01/22/25
  • Put/Call Vol Ratio 16.40
  • Today's Volume 87
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 8,247
  • Open Int (30-Day) 7,194

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.90
  • Low Estimate -1.09
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.10 +2.62%
on 11/05/25
9.16 -31.65%
on 10/09/25
-1.74 (-21.75%)
since 10/07/25
3-Month
6.10 +2.62%
on 11/05/25
9.16 -31.65%
on 10/09/25
-1.20 (-16.09%)
since 08/07/25
52-Week
6.10 +2.62%
on 11/05/25
25.39 -75.34%
on 11/11/24
-18.44 (-74.66%)
since 11/07/24

Most Recent Stories

More News
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies ...

BCYC : 6.34 (-2.61%)
3 Stocks to Buy Under $10 That Could Triple From Here

Not all great investment opportunities are expensive.

IOVA : 2.15 (-7.14%)
BCYC : 6.34 (-2.61%)
SANA : 3.87 (-4.44%)
Bicycle Therapeutics Strengthens Board of Directors with New Appointments

Roger Dansey, M.D., formerly Pfizer and Seagen, and Hervé Hoppenot, of Incyte and formerly Novartis Oncology, bring extensive drug development and commercialization expertise ...

BCYC : 6.34 (-2.61%)
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for...

BCYC : 6.34 (-2.61%)
Why Shares of Bicycle Therapeutics Were Rising on Monday

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.

BCYC : 6.34 (-2.61%)
NVS : 126.37 (-0.16%)
Why Bicycle Therapeutics Stock Raced Ahead Today

The company's latest attempt at capital raising seems to be having enviable success.

BCYC : 6.34 (-2.61%)
JEF : 53.19 (-0.26%)
GS : 779.16 (-1.07%)
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 6.34 (-2.61%)
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 6.34 (-2.61%)
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 6.34 (-2.61%)
Bicycle Therapeutics Enhances Leadership Team with Key Appointments

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 6.34 (-2.61%)

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 7.03
2nd Resistance Point 6.82
1st Resistance Point 6.66
Last Price 6.34
1st Support Level 6.29
2nd Support Level 6.08
3rd Support Level 5.92

See More

52-Week High 25.39
Fibonacci 61.8% 18.02
Fibonacci 50% 15.74
Fibonacci 38.2% 13.47
Last Price 6.34
52-Week Low 6.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar